Clinical trial
A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the…
NCT00405080 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00405080 |
|---|---|
| Title | A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant). |
| Official title | An Open-Label, Two Period, Fixed Sequence Study of Healthy Subjects to Assess the Effect of Repeat Oral Dosing of [Rifampin] on the Pharmacokinetics of a Single Oral Dose of [GW679769] |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Nausea and Vomiting, Chemotherapy-Induced |
| Intervention type | Drug |
| Interventions | GW679769 (Casopitant) oral tablets, Rifampin oral capsules |
| Enrollment | 12 |
| Start date | Nov 11, 2006 |
| Primary completion | Jan 5, 2007 |
| Completion | Jan 5, 2007 |
| First posted | Nov 29, 2006 |
| Last update posted | Sep 12, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: